{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:52:39Z","timestamp":1766451159164,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802862"],"award-info":[{"award-number":["81802862"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017596","name":"Natural Science Basic Research Program of Shaanxi Province","doi-asserted-by":"publisher","award":["2020JQ-546"],"award-info":[{"award-number":["2020JQ-546"]}],"id":[{"id":"10.13039\/501100017596","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Personnel Training Specialized Research Foundation from the Second Affiliated Hospital of Xi\u2019an Jiaotong University","award":["RC(XM)202002"],"award-info":[{"award-number":["RC(XM)202002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Purinergic Signalling"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s11302-023-09947-w","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T05:02:40Z","timestamp":1684904560000},"page":"273-284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Potential role of the P2X7 receptor in the proliferation of human diffused large B-cell lymphoma"],"prefix":"10.1007","volume":"20","author":[{"given":"Xiao","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenwen","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,24]]},"reference":[{"key":"9947_CR1","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA et al (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24:679\u2013690. https:\/\/doi.org\/10.1038\/s41591-018-0016-8","journal-title":"Nat Med"},{"key":"9947_CR2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ccr.2013.12.012","volume":"25","author":"L Pasqualucci","year":"2014","unstructured":"Pasqualucci L, Dalla-Favera R (2014) SnapShot: diffuse large B cell lymphoma. Cancer Cell 25:132\u2013132. e131.\u00a0https:\/\/doi.org\/10.1016\/j.ccr.2013.12.012","journal-title":"Cancer Cell"},{"key":"9947_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nature08638","volume":"463","author":"RE Davis","year":"2010","unstructured":"Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB et al (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463:88\u201392. https:\/\/doi.org\/10.1038\/nature08638","journal-title":"Nature"},{"key":"9947_CR4","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1126\/science.1153629","volume":"319","author":"G Lenz","year":"2008","unstructured":"Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW et al (2008) Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319:1676\u20131679. https:\/\/doi.org\/10.1126\/science.1153629","journal-title":"Science"},{"key":"9947_CR5","doi-asserted-by":"publisher","first-page":"1058371","DOI":"10.3389\/fonc.2023.1058371","volume":"13","author":"J Kaur","year":"2023","unstructured":"Kaur J, Dora S (2023) Purinergic signaling: diverse effects and therapeutic potential in cancer. Front Oncol 13:1058371. https:\/\/doi.org\/10.3389\/fonc.2023.1058371","journal-title":"Front Oncol"},{"key":"9947_CR6","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41568-018-0037-0","volume":"18","author":"F Di Virgilio","year":"2018","unstructured":"Di Virgilio F, Sarti AC, Falzoni S, De Marchi E, Adinolfi E (2018) Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. Nat Rev Cancer 18:601\u2013618. https:\/\/doi.org\/10.1038\/s41568-018-0037-0","journal-title":"Nat Rev Cancer"},{"key":"9947_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s11302-013-9372-5","volume":"9","author":"G Burnstock","year":"2013","unstructured":"Burnstock G, Di Virgilio F (2013) Purinergic signalling and cancer. Purinergic Signal 9:491\u2013540. https:\/\/doi.org\/10.1007\/s11302-013-9372-5","journal-title":"Purinergic Signal"},{"key":"9947_CR8","doi-asserted-by":"publisher","first-page":"691956","DOI":"10.3389\/fonc.2021.691956","volume":"11","author":"Y Mai","year":"2021","unstructured":"Mai Y, Guo Z, Yin W, Zhong N, Dicpinigaitis PV, Chen R (2021) P2X receptors: potential therapeutic targets for symptoms Associated with Lung Cancer - A Mini Review. Front Oncol 11:691956. https:\/\/doi.org\/10.3389\/fonc.2021.691956","journal-title":"Front Oncol"},{"key":"9947_CR9","doi-asserted-by":"publisher","first-page":"5655","DOI":"10.1038\/onc.2013.565","volume":"33","author":"D Nagel","year":"2014","unstructured":"Nagel D, Vincendeau M, Eitelhuber AC, Krappmann D (2014) Mechanisms and consequences of constitutive NF-kappaB activation in B-cell lymphoid malignancies. Oncogene 33:5655\u20135665. https:\/\/doi.org\/10.1038\/onc.2013.565","journal-title":"Oncogene"},{"key":"9947_CR10","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1038\/onc.2010.593","volume":"30","author":"B Jelassi","year":"2011","unstructured":"Jelassi B, Chantome A, Alcaraz-Perez F, Baroja-Mazo A, Cayuela ML, Pelegrin P et al (2011) P2X(7) receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness. Oncogene 30:2108\u20132122. https:\/\/doi.org\/10.1038\/onc.2010.593","journal-title":"Oncogene"},{"key":"9947_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11302-015-9493-0","volume":"12","author":"G Burnstock","year":"2016","unstructured":"Burnstock G (2016) P2X ion channel receptors and inflammation. Purinergic Signal 12:59\u201367. https:\/\/doi.org\/10.1007\/s11302-015-9493-0","journal-title":"Purinergic Signal"},{"key":"9947_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11302-017-9593-0","volume":"14","author":"G Burnstock","year":"2018","unstructured":"Burnstock G, Knight GE (2018) The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression. Purinergic Signal 14:1\u201318. https:\/\/doi.org\/10.1007\/s11302-017-9593-0","journal-title":"Purinergic Signal"},{"key":"9947_CR13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s12015-016-9651-y","volume":"12","author":"W Feng","year":"2016","unstructured":"Feng W, Yang F, Wang R, Yang X, Wang L, Chen C et al (2016) High level P2X7-Mediated signaling impairs function of hematopoietic Stem\/Progenitor cells. Stem Cell Rev Rep 12:305\u2013314. https:\/\/doi.org\/10.1007\/s12015-016-9651-y","journal-title":"Stem Cell Rev Rep"},{"key":"9947_CR14","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3324\/haematol.2019.243360","volume":"106","author":"W Feng","year":"2021","unstructured":"Feng W, Yang X, Wang L, Wang R, Yang F, Wang H et al (2021) P2X7 promotes the progression of MLL-AF9 induced acute myeloid leukemia by upregulation of Pbx3. Haematologica 106:1278\u20131289. https:\/\/doi.org\/10.3324\/haematol.2019.243360","journal-title":"Haematologica"},{"key":"9947_CR15","doi-asserted-by":"publisher","unstructured":"Morgan R, Pandha HS (2020) PBX3 in Cancer. Cancers (Basel) 12. https:\/\/doi.org\/10.3390\/cancers12020431","DOI":"10.3390\/cancers12020431"},{"key":"9947_CR16","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1182\/blood.v99.2.706","volume":"99","author":"E Adinolfi","year":"2002","unstructured":"Adinolfi E, Melchiorri L, Falzoni S, Chiozzi P, Morelli A, Tieghi A et al (2002) P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood 99:706\u2013708. https:\/\/doi.org\/10.1182\/blood.v99.2.706","journal-title":"Blood"},{"key":"9947_CR17","doi-asserted-by":"publisher","unstructured":"He X, Wan J, Yang X, Zhang X, Huang D, Li X et al (2021) Bone marrow niche ATP levels determine leukemia-initiating cell activity via P2X7 in leukemic models. J Clin Invest 131. https:\/\/doi.org\/10.1172\/JCI140242","DOI":"10.1172\/JCI140242"},{"key":"9947_CR18","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/bph.15299","volume":"178","author":"P Illes","year":"2021","unstructured":"Illes P, Muller CE, Jacobson KA, Grutter T, Nicke A, Fountain SJ et al (2021) Update of P2X receptor properties and their pharmacology: IUPHAR Review 30. Br J Pharmacol 178:489\u2013514. https:\/\/doi.org\/10.1111\/bph.15299","journal-title":"Br J Pharmacol"},{"key":"9947_CR19","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z (2017) GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 45:W98\u2013W102. https:\/\/doi.org\/10.1093\/nar\/gkx247","journal-title":"Nucleic Acids Res"},{"key":"9947_CR20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s12064-012-0162-3","volume":"131","author":"GP Wagner","year":"2012","unstructured":"Wagner GP, Kin K, Lynch VJ (2012) Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples. Theory Biosci 131:281\u2013285. https:\/\/doi.org\/10.1007\/s12064-012-0162-3","journal-title":"Theory Biosci"},{"key":"9947_CR21","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nature07968","volume":"459","author":"M Compagno","year":"2009","unstructured":"Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q et al (2009) Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459:717\u2013721. https:\/\/doi.org\/10.1038\/nature07968","journal-title":"Nature"},{"key":"9947_CR22","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1084\/jem.20080809","volume":"205","author":"V Brune","year":"2008","unstructured":"Brune V, Tiacci E, Pfeil I, Doring C, Eckerle S, van Noesel CJ et al (2008) Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med 205:2251\u20132268. https:\/\/doi.org\/10.1084\/jem.20080809","journal-title":"J Exp Med"},{"key":"9947_CR23","doi-asserted-by":"publisher","first-page":"10534","DOI":"10.1073\/pnas.1204127109","volume":"109","author":"C Vicente-Duenas","year":"2012","unstructured":"Vicente-Duenas C, Fontan L, Gonzalez-Herrero I, Romero-Camarero I, Segura V, Aznar MA et al (2012) Expression of MALT1 oncogene in hematopoietic stem\/progenitor cells recapitulates the pathogenesis of human lymphoma in mice. Proc Natl Acad Sci U S A 109:10534\u201310539. https:\/\/doi.org\/10.1073\/pnas.1204127109","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9947_CR24","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.1182\/blood-2011-03-344374","volume":"118","author":"C Gomez-Abad","year":"2011","unstructured":"Gomez-Abad C, Pisonero H, Blanco-Aparicio C, Roncador G, Gonzalez-Menchen A, Martinez-Climent JA et al (2011) PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. Blood 118:5517\u20135527. https:\/\/doi.org\/10.1182\/blood-2011-03-344374","journal-title":"Blood"},{"key":"9947_CR25","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1038\/leu.2016.135","volume":"30","author":"D Juskevicius","year":"2016","unstructured":"Juskevicius D, Lorber T, Gsponer J, Perrina V, Ruiz C, Stenner-Liewen F et al (2016) Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis. Leukemia 30:2385\u20132395. https:\/\/doi.org\/10.1038\/leu.2016.135","journal-title":"Leukemia"},{"key":"9947_CR26","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/ijc.29072","volume":"136","author":"R Scholtysik","year":"2015","unstructured":"Scholtysik R, Kreuz M, Hummel M, Rosolowski M, Szczepanowski M, Klapper W et al (2015) Characterization of genomic imbalances in diffuse large B-cell lymphoma by detailed SNP-chip analysis. Int J Cancer 136:1033\u20131042. https:\/\/doi.org\/10.1002\/ijc.29072","journal-title":"Int J Cancer"},{"key":"9947_CR27","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1200\/JCO.2014.57.7080","volume":"33","author":"K Dybkaer","year":"2015","unstructured":"Dybkaer K, Bogsted M, Falgreen S, Bodker JS, Kjeldsen MK, Schmitz A et al (2015) Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. J Clin Oncol 33:1379\u20131388. https:\/\/doi.org\/10.1200\/JCO.2014.57.7080","journal-title":"J Clin Oncol"},{"key":"9947_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.exphem.2015.12.007","volume":"44","author":"SC Marques","year":"2016","unstructured":"Marques SC, Ranjbar B, Laursen MB, Falgreen S, Bilgrau AE, Bodker JS et al (2016) High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma. Exp Hematol 44:238\u2013246e232. https:\/\/doi.org\/10.1016\/j.exphem.2015.12.007","journal-title":"Exp Hematol"},{"key":"9947_CR29","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/bjh.12045","volume":"159","author":"SL Barrans","year":"2012","unstructured":"Barrans SL, Crouch S, Care MA, Worrillow L, Smith A, Patmore R et al (2012) Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-cell lymphoma and predict clinical outcome. Br J Haematol 159:441\u2013453. https:\/\/doi.org\/10.1111\/bjh.12045","journal-title":"Br J Haematol"},{"key":"9947_CR30","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1158\/1078-0432.CCR-17-1041","volume":"24","author":"C Tarantelli","year":"2018","unstructured":"Tarantelli C, Gaudio E, Arribas AJ, Kwee I, Hillmann P, Rinaldi A et al (2018) PQR309 is a Novel Dual PI3K\/mTOR inhibitor with Preclinical Antitumor Activity in Lymphomas as a single Agent and in combination therapy. Clin Cancer Res 24:120\u2013129. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1041","journal-title":"Clin Cancer Res"},{"key":"9947_CR31","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1158\/1078-0432.CCR-11-1407","volume":"18","author":"AM Petrich","year":"2012","unstructured":"Petrich AM, Leshchenko V, Kuo PY, Xia B, Thirukonda VK, Ulahannan N et al (2012) Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma. Clin Cancer Res 18:2534\u20132544. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1407","journal-title":"Clin Cancer Res"},{"key":"9947_CR32","doi-asserted-by":"publisher","first-page":"36179","DOI":"10.1074\/jbc.M110.128488","volume":"285","author":"JH Chong","year":"2010","unstructured":"Chong JH, Zheng GG, Ma YY, Zhang HY, Nie K, Lin YM et al (2010) The hyposensitive N187D P2X7 mutant promotes malignant progression in nude mice. J Biol Chem 285:36179\u201336187. https:\/\/doi.org\/10.1074\/jbc.M110.128488","journal-title":"J Biol Chem"},{"key":"9947_CR33","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1159\/000134124","volume":"71","author":"ML Summar","year":"1995","unstructured":"Summar ML, Dasouki MJ, Schofield PJ, Krishnamani MR, Vnencak-Jones C, Tuchman M et al (1995) Physical and linkage mapping of human carbamyl phosphate synthetase I (CPS1) and reassignment from 2p to 2q35. Cytogenet Cell Genet 71:266\u2013267. https:\/\/doi.org\/10.1159\/000134124","journal-title":"Cytogenet Cell Genet"},{"key":"9947_CR34","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1146\/annurev.nutr.22.110801.140547","volume":"22","author":"SM Morris Jr","year":"2002","unstructured":"Morris SM Jr (2002) Regulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr 22:87\u2013105. https:\/\/doi.org\/10.1146\/annurev.nutr.22.110801.140547","journal-title":"Annu Rev Nutr"},{"key":"9947_CR35","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","volume":"2016","author":"B Coiffier","year":"2016","unstructured":"Coiffier B, Sarkozy C (2016) Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematol Am Soc Hematol Educ Program 2016:366\u2013378. https:\/\/doi.org\/10.1182\/asheducation-2016.1.366","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"9947_CR36","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P et al (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857\u20131861. https:\/\/doi.org\/10.1182\/blood-2006-08-038257","journal-title":"Blood"},{"key":"9947_CR37","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M et al (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28:4184\u20134190. https:\/\/doi.org\/10.1200\/JCO.2010.28.1618","journal-title":"J Clin Oncol"},{"key":"9947_CR38","doi-asserted-by":"publisher","unstructured":"Chen YJ, Abila B, Mostafa Kamel Y (2023) CAR-T: what is next? Cancers. 15. https:\/\/doi.org\/10.3390\/cancers15030663","DOI":"10.3390\/cancers15030663"},{"key":"9947_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18656","author":"R Del Toro-Mijares","year":"2023","unstructured":"Del Toro-Mijares R, Oluwole O, Jayani RV, Kassim AA, Savani BN, Dholaria B (2023) Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: current challenges and therapeutic options. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.18656","journal-title":"Br J Haematol"},{"key":"9947_CR40","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503\u2013511. https:\/\/doi.org\/10.1038\/35000501","journal-title":"Nature"},{"key":"9947_CR41","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.ccr.2013.05.002","volume":"23","author":"L Chen","year":"2013","unstructured":"Chen L, Monti S, Juszczynski P, Ouyang J, Chapuy B, Neuberg D et al (2013) SYK inhibition modulates distinct PI3K\/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell 23:826\u2013838. https:\/\/doi.org\/10.1016\/j.ccr.2013.05.002","journal-title":"Cancer Cell"},{"key":"9947_CR42","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1096\/fj.09-153601","volume":"24","author":"E Adinolfi","year":"2010","unstructured":"Adinolfi E, Cirillo M, Woltersdorf R, Falzoni S, Chiozzi P, Pellegatti P et al (2010) Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor. FASEB J 24:3393\u20133404. https:\/\/doi.org\/10.1096\/fj.09-153601","journal-title":"FASEB J"},{"key":"9947_CR43","doi-asserted-by":"publisher","first-page":"e107224","DOI":"10.1371\/journal.pone.0107224","volume":"9","author":"AL Giuliani","year":"2014","unstructured":"Giuliani AL, Colognesi D, Ricco T, Roncato C, Capece M, Amoroso F et al (2014) Trophic activity of human P2X7 receptor isoforms a and B in osteosarcoma. PLoS ONE 9:e107224. https:\/\/doi.org\/10.1371\/journal.pone.0107224","journal-title":"PLoS ONE"},{"key":"9947_CR44","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/s41419-020-03058-9","volume":"11","author":"A Pegoraro","year":"2020","unstructured":"Pegoraro A, Orioli E, De Marchi E, Salvestrini V, Milani A, Di Virgilio F et al (2020) Differential sensitivity of acute myeloid leukemia cells to daunorubicin depends on P2X7A versus P2X7B receptor expression. Cell Death Dis 11:876. https:\/\/doi.org\/10.1038\/s41419-020-03058-9","journal-title":"Cell Death Dis"},{"key":"9947_CR45","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41419-022-04526-0","volume":"13","author":"M Zanoni","year":"2022","unstructured":"Zanoni M, Sarti AC, Zamagni A, Cortesi M, Pignatta S, Arienti C et al (2022) Irradiation causes senescence, ATP release, and P2X7 receptor isoform switch in glioblastoma. Cell Death Dis 13:80. https:\/\/doi.org\/10.1038\/s41419-022-04526-0","journal-title":"Cell Death Dis"},{"key":"9947_CR46","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.exphem.2021.10.001","volume":"104","author":"X He","year":"2021","unstructured":"He X, Zhang Y, Xu Y, Xie L, Yu Z, Zheng J (2021) Function of the P2X7 receptor in hematopoiesis and leukemogenesis. Exp Hematol 104:40\u201347. https:\/\/doi.org\/10.1016\/j.exphem.2021.10.001","journal-title":"Exp Hematol"},{"key":"9947_CR47","doi-asserted-by":"publisher","first-page":"e60184","DOI":"10.1371\/journal.pone.0060184","volume":"8","author":"S Bian","year":"2013","unstructured":"Bian S, Sun X, Bai A, Zhang C, Li L, Enjyoji K et al (2013) P2X7 integrates PI3K\/AKT and AMPK-PRAS40-mTOR signaling pathways to mediate Tumor Cell Death. PLoS ONE 8:e60184. https:\/\/doi.org\/10.1371\/journal.pone.0060184","journal-title":"PLoS ONE"},{"key":"9947_CR48","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/labinvest.3700699","volume":"88","author":"SL Butler","year":"2008","unstructured":"Butler SL, Dong H, Cardona D, Jia M, Liu C (2008) The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1. Lab Invest 88:78\u201388.\u00a0https:\/\/doi.org\/10.1038\/labinvest.3700699","journal-title":"Lab Invest"},{"key":"9947_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnci\/djw231","volume":"109","author":"M elikta","year":"2017","unstructured":"elikta M, Tanaka I, Tripathi SC, Fahrmann JF, Aguilar-Bonavides C, Villalobos P et al (2017) Role of CPS1 in cell growth, metabolism, and prognosis in LKB1-Inactivated lung adenocarcinoma. J Natl Cancer Inst 109:1. https:\/\/doi.org\/10.1093\/jnci\/djw231","journal-title":"J Natl Cancer Inst"}],"container-title":["Purinergic Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-023-09947-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11302-023-09947-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-023-09947-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T08:15:17Z","timestamp":1718698517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11302-023-09947-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,24]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["9947"],"URL":"https:\/\/doi.org\/10.1007\/s11302-023-09947-w","relation":{},"ISSN":["1573-9538","1573-9546"],"issn-type":[{"type":"print","value":"1573-9538"},{"type":"electronic","value":"1573-9546"}],"subject":[],"published":{"date-parts":[[2023,5,24]]},"assertion":[{"value":"26 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no other competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that there is no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}